ClinicalTrials.gg
Active, not recruitingNCT07187115OPTIMIZEUpdated Oct 23, 2026

A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation

An interventional study of FARAPOINT Pulsed Field Ablation System and OptiMap System (non-ablative) in Atrial Fibrillation (AF) and Persistant Atrial Fibrillation, sponsored by Boston Scientific Corporation. Active, not recruiting at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Boston Scientific Corporation · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
699
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 73 studies in Atrial Fibrillation by Boston Scientific Corporation — 8 open to participants now, 20 under way, none of them phase 3. Atrial Fibrillation · Boston Scientific Corporation.

Planned enrollment
7th of 51
699 · median 200
Started
2025
with 8 others
No phase
45 of 73
8 open now
Primary completion
2027-01
later than 4 of 19 live
Registered
66th of 73
by date

Among the 73 studies in Atrial Fibrillation by Boston Scientific Corporation, this one is the 7th largest by planned enrollment of the 51 interventional ones that give a count, is one of 9 that started in 2025, is one of 45 with no phase, reaches primary completion later than 4 of the 19 other live ones, and was the 66th registered.

Atrial Fibrillation

4,016 studies on the registry are indexed under Atrial Fibrillation; 963 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

8 of the 73 studies in Atrial Fibrillation by Boston Scientific Corporation are open now, in 11 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 609 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Atrial Fibrillation by Boston Scientific Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to establish the safety of the pulsed field ablation (PFA) therapy of Pulmonary Veins and Electrographic Flow (EGF) identified extra-PV sources of atrial fibrillation (PVI + EGF ablation of sources) and to demonstrate its non-inferiority in effectiveness compared to PFA of Pulmonary Veins and LA Posterior Wall (PVI+ PWA) in the treatment of de novo symptomatic drug-refractory persistent atrial fibrillation (PersAF).

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Persistant Atrial Fibrillation

Browse trials for

Keywords

  • FARAPULSE
  • FARAPOINT
  • OptiMap
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age, or older if required by local law
  2. Have symptomatic drug-refractory1, persistent AF2, confirmed by both:

    • Documentation, such as physician note, of persistent continuous AF for > 7 days and ≤ 365 days and the arrhythmia symptoms
    • Documentation, within 180 days of enrollment date of either:

      • A 24-hour continuous recording confirming continuous AF or
      • Two (2) ECGs (from any regulatory cleared rhythm monitoring device) showing continuous AF taken at least 7 days apart
  3. Willing and capable of providing
  4. Willing and capable of participating in all follow-up assessments and testing associated with this clinical investigation at an approved clinical center
  5. Willing to receive LUX-Dx™ insertable cardiac monitor (ICM) during the study or already has a LUX-Dx™ ICM that was inserted ≤ 6 months (i.e., within 180 days) of consent, and willing to comply to the LUX-Dx Latitude Clarity transmission instructions

Exclusion criteria

Exclusion Criteria:

  1. Any of the following atrial conditions:

    1. Left atrial anteroposterior diameter ≥ 5.5 cm, or if1 LA diameter not available, non-indexed volume >100 ml (physician note or imaging)
    2. Any prior left atrial ablation
    3. Any prior atrial surgery
    4. Current atrial myxoma
    5. Current left atrial thrombus
    6. Any PV abnormality, stenosis, or stenting (common and middle PVs are admissible)
  2. Any of the following cardiovascular conditions:

    1. History of sustained ventricular tachycardia or any ventricular fibrillation
    2. Severe right ventricular dysfunction with documented echocardiography and/or hemodynamic data, per Investigator's discretion
    3. AF that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes
    4. Cardiac devices and implants:

      • Current or anticipated pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy devices
      • Implantable loop recorder, other than LUX-Dx
      • Interatrial baffle, patent foramen ovale or atrial septal defect closure device or patch
      • Any left atrial appendage closure or occlusion device
    5. Presence of any of the following valvular conditions:

      • Any prosthetic heart valve, stenotic valves, ring or repair
      • Moderate to severe mitral valve stenosis
      • More than moderate mitral regurgitation
    6. Hypertrophic or amyloid cardiomyopathy
    7. Any IVC filter, known inability to obtain vascular access or other to femoral access
    8. Awaiting cardiac transplantation or other planned cardiac surgery within the next 12 months
    9. Severe right ventricular dysfunction with documented echocardiography and/or hemodynamic data.
  3. Any of the following conditions at Baseline:

    1. Heart failure associated with Class III or IV
    2. Most recent documented \< 40% within the previous 12 months
    3. (BMI) > 45.0
    4. Known coagulopathy or bleeding disorder
    5. Contraindication to, or unwillingness to use systemic anticoagulation, or acceptable alternatives, pre-, intra- and post-procedure to achieve adequate anticoagulation
    6. Women who are confirmed to be pregnant or lactating at the time of the ablation procedure
    7. Severe lung disease, severe pulmonary hypertension, or any lung disease involving abnormal blood gases or requiring supplemental oxygen
    8. Active (other than squamous cell carcinoma)
    9. gastrointestinal problems involving the esophagus or stomach including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenal ulceration
    10. Known active systemic infection
    11. Untreated diagnosed obstructive sleep apnea with apnea hypopnea index classification of severe (>30 pauses per hour) as per the guidelines
    12. Predicted less than one year per investigator medical judgement
    13. Subjects who are currently enrolled in another study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the Sponsor to determine eligibility
    14. Required use of phosphodiesterase inhibitors within 24 hours of the ablation procedure
    15. Uncontrolled hypertension (SBP > 160 mmHg or DBP > 95 mmHg on two (2) BP measurements at baseline assessment not attributable to white coat syndrome per Investigator opinion
    16. CHA2DS2-VASc score ≥ 5
    17. Known allergic drug reaction to nitroglycerin (excluding hypotension)
    18. Unwillingness to receive, or unable to tolerate, a subcutaneous, chronically inserted LUX-Dx ICM device
  4. Any of the following congenital conditions:

    1. Congenital heart disease with any clinically significant residual anatomic or conduction abnormality
    2. History of known congenital methemoglobinemia
    3. History of known G6PD deficiency
  5. Any of the following conditions in the medical history:

    1. Solid organ or hematologic transplant, or currently being evaluated for a transplant
    2. Any prior history or current evidence of hemi-diaphragmatic paralysis or paresis
    3. Any documented history of Prinzmetal Angina or severe non-revascularizable coronary disease
    4. Renal insufficiency if an estimated (eGFR) is \< 30 mL / min / 1.73 m2, or with any history of renal dialysis or renal transplant
    5. Any other general health condition that, in the investigator's medical opinion, would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation.
  6. Any of the following events less than or equal to 90 days of the consent date:

    1. Myocardial infarction (MI), unstable angina or coronary intervention
    2. Any cardiac surgery
    3. Heart failure hospitalization
    4. Pericarditis or symptomatic pericardial effusion
    5. Gastrointestinal bleeding
    6. Stroke, , or intracranial bleeding
    7. Any active non-neurologic thrombus and/or thromboembolic event
    8. Carotid stenting or endarterectomy
    9. Uncontrolled diabetes mellitus or a recorded > 8.0%
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
699 participants (estimated)

Study arms

  • Active comparator
    Control Arm

    PVI + PWA: The Control Arm, consisting of subjects undergoing PVI + PWA. PWA will be performed adjunctive to PVI per protocol Section 10.8.10. Following confirmation of PWA, EGF mapping will be performed in the LA and RA, while Investigators, lab/nursing staff, and research personnel are blinded to the EGF maps.

    Device: OptiMap System (non-ablative) · Device: FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System

  • Experimental
    Treatment Arm

    PVI + EGF source(s) ablation: The Treatment Arm, consisting of subjects undergoing PVI + EGF source(s) ablation. Adjunctive to PVI, the EGF-identified active sources above threshold will be ablated per protocol Section 10.8.11. If following PVI, a narrow channel that is approximately ≤ 1 cm is identified in the LAPW, ablation may be performed using the FARAPOINT Catheter.

    Device: FARAPOINT Pulsed Field Ablation System · Device: OptiMap System (non-ablative) · Device: FARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System

Interventions

  • DeviceFARAPOINT Pulsed Field Ablation System

    A component of the FARAPULSE Pulsed Field Ablation (PFA) System and is a multi-electrode bidirectional, deflectable percutaneous catheter, an adjunctive catheter designed to create focal-type lesions for the creation of an ablation line between the inferior vena cava and the tricuspid valve.

  • DeviceOptiMap System (non-ablative)

    An electrophysiology mapping system that uses a proprietary algorithm to analyze electrogram signals.

    Also known as: Ablamap System

  • DeviceFARAPULSE Pulsed Field Ablation (PFA) System and Opal HDx Mapping System

    All subjects will undergo electroanatomical mapping of the entire left atrium with the FARAWAVE NAV Catheter and Opal HDx Mapping System, followed by PFA PVI with the FARAWAVE NAV PFA Catheter, per the instructions of use.

06

What researchers measure

Primary outcomes

  1. Primary Safety Endpoint

    The primary safety endpoint is the rate of ITT subjects in the PVI+EGF arm with one or more of the following serious device- or procedure-related Composite Adverse Events (CAEs) assessed through 60 days following the Index Procedure.

    Time frame: 60 Days

  2. Primary Effectiveness Endpoint

    The primary effectiveness endpoint is the rate of ITT subjects with treatment success in the PVI+EGF arm vs. the PVI+PWA control arm through Day 365, aiming to demonstrate non-inferiority of PVI+EGF compared to the PVI+PWA control.

    Time frame: 365 Days

Secondary outcomes

  1. Secondary Effectiveness Endpoint

    The secondary effectiveness endpoint is a test for superiority in Treatment Success between the Treatment Arm and the Control Arm. The test for superiority will only be conducted if the non-inferiority test for the PEE is passed and the result favors the Treatment Arm.

    Time frame: 365 Days

07

Study locations

15 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jan 2027, 14 months after the start.

Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 14 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2025
First posted
Sep 22, 2025
StartActual
Nov 7, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07187115
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Nov 7, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion